Cargando…

Co-Targeting of JNK and HUNK in Resistant HER2-Positive Breast Cancer

Strategies for successful primary treatment of HER2-positive breast cancer include use of the HER2 inhibitors trastuzumab or lapatinib in combination with standard chemotherapy. While successful, many patients develop resistance to these HER2 inhibitors indicating an unmet need. Consequently, curren...

Descripción completa

Detalles Bibliográficos
Autores principales:	Phelps-Polirer, Kendall, Abt, Melissa A., Smith, Danzell, Yeh, Elizabeth S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821489/ https://www.ncbi.nlm.nih.gov/pubmed/27045589 http://dx.doi.org/10.1371/journal.pone.0153025

Ejemplares similares

HUNK phosphorylates EGFR to regulate breast cancer metastasis
por: Williams, Carly B., et al.
Publicado: (2019)

Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors
por: Yeh, Elizabeth S., et al.
Publicado: (2014)

Correction: HUNK phosphorylates EGFR to regulate breast cancer metastasis
por: Williams, Carly B., et al.
Publicado: (2021)

HUNK Phosphorylates Rubicon to Support Autophagy
por: Zambrano, Joelle N., et al.
Publicado: (2019)

HUNK Signaling in Metastatic Breast Cancer
por: Dilday, Tinslee, et al.
Publicado: (2020)

HUNK Gene Alterations in Breast Cancer
por: Ramos-Solis, Nicole, et al.
Publicado: (2022)

Hunk/Mak-v is a negative regulator of intestinal cell proliferation
por: Reed, Karen R, et al.
Publicado: (2015)

Generalized Granuloma Annulare Associated With Dupilumab Therapy
por: Phelps-Polirer, Kendall, et al.
Publicado: (2022)

Autophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast Cancer
por: Zambrano, Joelle, et al.
Publicado: (2016)

HER2-driven breast cancer suppression by the JNK signaling pathway
por: Itah, Zeynep, et al.
Publicado: (2023)

The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast
por: Lewis, Gary. D., et al.
Publicado: (2021)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
por: Watanabe, Satomi, et al.
Publicado: (2019)

Spontaneous Epithelial-Mesenchymal Transition and Resistance to HER-2-Targeted Therapies in HER-2-Positive Luminal Breast Cancer
por: Lesniak, David, et al.
Publicado: (2013)

Targeted therapy for HER2 positive breast cancer
por: Incorvati, Jason A, et al.
Publicado: (2013)

Dysregulated connexin 43 in HER2-positive drug resistant breast cancer cells enhances proliferation and migration
por: Yeh, Elizabeth S., et al.
Publicado: (2017)

HUNK inhibits epithelial-mesenchymal transition of CRC via direct phosphorylation of GEF-H1 and activating RhoA/LIMK-1/CFL-1
por: Han, Xiaoqi, et al.
Publicado: (2023)

Elaeagnus angustifolia Plant Extract Inhibits Epithelial-Mesenchymal Transition and Induces Apoptosis via HER2 Inactivation and JNK Pathway in HER2-Positive Breast Cancer Cells
por: Jabeen, Ayesha, et al.
Publicado: (2020)

Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers
por: Sun, Bowen, et al.
Publicado: (2019)

Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma
por: Peiró, G, et al.
Publicado: (2014)

Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents
por: Wang, Zhen-hao, et al.
Publicado: (2022)

Emerging Targeted Therapies for HER2-Positive Breast Cancer
por: Mercogliano, María Florencia, et al.
Publicado: (2023)

Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer
por: Hong, Joohyun, et al.
Publicado: (2022)

74. EFFICACY OF HER2-TARGETED THERAPY IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES: A NATIONAL ANALYSIS
por: Hulsbergen, Alexander, et al.
Publicado: (2020)

Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
por: Ding, Yi, et al.
Publicado: (2018)

Preclinical and Basic Research Strategies for Overcoming Resistance to Targeted Therapies in HER2-Positive Breast Cancer
por: Cao, Yi, et al.
Publicado: (2023)

Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer
por: He, Licai, et al.
Publicado: (2017)

Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer
por: Holloway, Ryan W., et al.
Publicado: (2021)

The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer
por: Bragina, O. D., et al.
Publicado: (2022)

Targeting HER2-positive breast cancer: advances and future directions
por: Swain, Sandra M., et al.
Publicado: (2022)

Targeting connexin 43 with α–connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1
por: Grek, Christina L, et al.
Publicado: (2015)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
por: Adam-Artigues, Anna, et al.
Publicado: (2022)

HER2-signaling pathway, JNK and ERKs kinases, and cancer stem-like cells are targets of Bozepinib
por: Ramírez, Alberto, et al.
Publicado: (2014)

TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
por: Gu, Yayun, et al.
Publicado: (2022)

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2019)

MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN
por: Ye, Xingming, et al.
Publicado: (2014)

Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer
por: Luque, Melani, et al.
Publicado: (2021)

Dynamic ultrasound molecular‐targeted imaging of senescence in evaluation of lapatinib resistance in HER2‐positive breast cancer
por: Chen, Xiaoyu, et al.
Publicado: (2023)

MZ1 co-operates with trastuzumab in HER2 positive breast cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2021)

Therapeutic siRNA for drug-resistant HER2-positive breast cancer
por: Gu, Shenda, et al.
Publicado: (2016)

HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
por: Pernas, Sonia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_842vkg09ois47io57oqjodj18v